Mölnlycke and Zuellig Pharma strengthen partnership for advanced wound care solutions in South-East Asia
The partnership will leverage deep expertise of both companies to improve range and availability of wound care products and solutions across the region
Mölnlycke and Zuellig Pharma have announced a new partnership that will focus on providing more advanced wound care products and solutions to patients and healthcare practitioners across South-East Asia. This strategic partnership follows Mölnlycke’s successful acquisition of SastoMed in July 2018, augmenting Mölnlycke’s range of wound care solutions with SastoMed’s ground-breaking, oxygen-therapy based solutions for chronic wounds (via its products Granulox® and Granudacyn®).
The commercialisation of Granulox and Granudacyn in South-East Asia was previously managed by SastoMed’s exclusive strategic partner, Zuellig Pharma, one of Asia’s largest healthcare services provider.
The new partnership will reflect Mölnlycke’s extensive experience in the marketing, medical and sales management of their advanced wound care portfolio (including Granulox and Granudaycn) while leveraging on Zuellig Pharma’s extensive network to ensure that their products become more assessible to the communities across Asia.
'We are pleased to continue working with our long-standing partner Zuellig Pharma. Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region,' says Richard Twomey, CEO of Mölnlycke.
'Zuellig Pharma is in a strong position to support growing healthcare needs in the region. This new strategic partnership with Mölnlycke is testament to the confidence our partners have in the work we do and will tap on the deep networks and capabilities we have established across the region to make healthcare more accessible in the communities we serve,' said John Graham, Senior Vice-President Commercial Solutions, Zuellig Pharma.
The partnership will roll out in specific countries in South-East Asia, expanding to more markets over time.
For more information, please contact:
Jenny Johansson, Global Manager, Corporate Communicatons
jenny.johansson@molnlycke.com
Phone: +46 (0) 739 41 29 23
Lim Ee Guan, Director, Corporate Communications
eglim@zuelligpharma.com
Phone: +65 6708 8126
About Mölnlycke
Mölnlycke is a world leading medical solutions company. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings. Our solutions provide value for money, supported by clinical and health economic evidence.
Mölnlycke was founded in 1849. Nowadays, our solutions are available in around 100 countries; we are the number one global provider of advanced wound care and single-use surgical products; and we are Europe’s largest provider of customized trays. Our headquarters are in Gothenburg, Sweden and we have about 7,700 employees around the world. Learn more at molnlycke.com
About Zuellig Pharma
Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible. We provide world-class distribution, commercial and digital services to support the growing healthcare needs in this region.
The company started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with 13,000 employees. We serve over 350,000 medical facilities and work with more than 1,000 clients, including the top 20 pharmaceutical companies in the world.
More recently, we launched our Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, our teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.
